One shot before surgery: new hope for fighting skin cancer early
NCT ID NCT07448831
Summary
This study is testing if giving a single dose of the immunotherapy drug pembrolizumab six weeks before surgery can help the body's immune system attack high-risk melanoma cells that might be too small to see on scans. It involves 49 adults with high-risk melanoma that hasn't visibly spread. The goal is to see if this early treatment can reduce microscopic cancer spread and lower the chance of the cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UZ Brussel
RECRUITINGJette, Brussels Capital, 1090, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.